For adults with confirmed hypertension and known CVD or 10-year ASCVD event risk of 10% or higher (see Section 8.1.2), a BP target of less than 130/80 mm Hg is DBP: C-EO IIb SBP: B-NR 2. For adults with confirmed hypertension, without additional markers of increased CVD risk, a BP target of less than 130/80 mm Hg may be reasonable.S8.1.5-6 S8.1.5-9 DBP: C-EO SR indicates systematic review. Synopsis Refer to the Systematic Review for the 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults for the complete systematic evidence review for additional data Several trials have tested whether more intensive BP control improves major CVD outcomes. Meta- analyses and systematic reviews of these trials provide strong support for the more intensive approach, but the data are less clear in identification of a specific optimal BP target.S8.1.5-1 Recent trials that address optimal BP targets include SPRINT and ACCORD (Action to Control Cardiovascular Risk in Diabetes), with targets for more inten- sive (SBP <120 mm Hg) and standard (SBP <140 mm Hg) and SPS-3, with a more intensive target These trials yielded mixed results in achieving their primary endpoints. SPRINT was stopped early, after a median follow-up of 3.26 years, when more intensive treatment resulted in a significant reduction in the primary outcome (a CVD composite) and in all-cause mortality rate. In ACCORD, more intensive BP treatment failed to demonstrate a significant reduction in the primary outcome (a CVD com- posite). However, the incidence of stroke, a component of the primary outcome, was significantly reduced. 